HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 10, October 2019 – Disruptive Urban Farming — Microbes, Plasmids, and Recycling       » Chinese scientist find new possibilities in dengue virus control       » 50 young scientists awarded with the inaugural XPLORER PRIZE       » Entering the China market to provide regional support       » Science, Tech, and policies convene for a sustainable future      
INSIDE INDUSTRY
Asia’s first FemTech innovations group to offer healthcare solutions unique to Asian women
Merger between INEX and Nova Satra creates a strong commercial portfolio of validated tests in prenatal health and cancer detection

Singapore molecular diagnostics groups INEX Innovations Exchange Pte. Ltd. (INEX) and Nova Satra Dx Pte. Ltd. (Nova Satra) announced in August 2019 the merger of the two companies to create INEX INNOVATE. The new company will be focused on addressing the unmet need for faster and more accurate diagnostics testing and precision healthcare for Asian women.

This merger will create Asia’s first FemTech company with a strong portfolio of intellectual property comprising more than 45 key patents and nine trademarks worldwide. The company’s women’s reproductive health solution have been commercialised in multiple markets across Asia-Pacific and have been growing sales in existing markets whilst expanding into new ones such as Indonesia and Bangladesh.

The pipeline of new technologies the company is developing includes OvaCis, a point of care kit that can distinguish benign from malignant ovarian cysts in 5 minutes, Zena, a blood based test for the early detection of ovarian cancer, and NovoTectTM BC, one of the first epigenetics-based early detection test for breast cancer in Asian women. INEX INNOVATE plans to commercialize these technologies by 2020 across Asia.

INEX INNOVATE’s technology is focused on providing precision diagnosis and care for women across the Asian phenotype. By integrating laboratories, research, development and distribution functions from the two companies, INEX INNOVATE will benefit from improved cost efficiencies, expanded R&D activities, fast tracked commercialisation of its pipeline assets, and market expansion.

The deal, valued at US$72 million, is backed by institutional investors including Genting, Enterprise Singapore and SNS Holdings.

Mr. Kane Black, Chief Executive Officer (CEO) of Nova Satra, will assume the role of Chief Executive Officer of INEX INNOVATE. President & Chief Operating Officer of Genting Berhad, Mr. Tan Kong Han will join the board of INEX INNOVATE with Genting’s SVP of Legal Ms. Goh Lee Sian as alternate Director.

The new CEO for INEX INNOVATE, Mr Kane Black commented, “We are delighted to launch INEX INNOVATE and will continue to work to empower Asian women in the management of their own health through improved access to rapid, accurate diagnosis and technologies. This merger is a strategic step to expedite that ambition. Asian countries now account for 40 percent of breast cancer cases worldwide and 37 percent of caners diagnosed in females are in Asia. INEX INNOVATE is now well-equipped to bring our proprietary tests to more patients and physicians in Asia and beyond.”

Click here for the complete issue.

NEWS CRUNCH  
news The Proteona Oncology Challenge using ESCAPETM Single Cell Proteogenomic Analysis
news New computational fluid dynamics solution for modeling aerosol mixtures in biomedical and environmental research
news Medial Fair Thailand opened on 11th September 2019 with a focus on future-proofing Thailand's healthcare industry to meet the challenges and opportunities of the next decade
news Biofuel Producers and Users to Convene in Singapore for Global Biofuels Summit
PR NEWSWIRE  
Asia Pacific Biotech News
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
August:
Digitalization vs Digitization — Exploring Emerging Trends in Healthcare
September:
Healthy Ageing — How Science is chipping in
October:
Disruptive Urban Farming — Microbes, Plasmids, and Recycling
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy